TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients with tumors that have progressed on endocrine therapy and/or are not eligible for endocrine therapy had limited treatment options beyond chemotherapy. Antibody-drug conjugates are a novel and promising treatment class in this setting. Datopotamab deruxtecan (Dato-DXd) consists of a TROP2-directed humanized IgG1 monoclonal antibody attached via a serum-stable cleavable linker to a topoisomerase I inhibitor payload. TROPION-Breast01 is an ongoing phase 3 study that is evaluating the efficacy and safety of Dato-DXd compared with investigator's choice of standard-of-care chemotherapy in patients with inoperable or metastatic HR+/HER2- breast cancer who have received one or two prior lines of systemic chemotherapy in the inoperable or metastatic setting. Clinical Trial Registration: NCT05104866 (ClinicalTrials.gov)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationRibociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Self-citationMONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Self-citationSacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711
Self-citationCortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025
Self-citationOverall survival with ribociclib plus endocrine therapy in breast cancer
Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001
Self-citationOverall survival with ribociclib plus fulvestrant in advanced breast cancer
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911149 · Cited by 865
Self-citationOgitani, Y., Hagihara, K., Oitate, M., Naito, H., & Agatsuma, T. (2016) · Cancer Science · doi:10.1111/cas.12966 · Cited by 751
Okajima, D., Yasuda, S., Maejima, T., Karibe, T., Sakurai, K., Aida, T., Toki, T., Yamaguchi, J., Kitamura, M., Kamei, R., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0206 · Cited by 339
Cited by
Abelman, R. O., Wu, B., Barnes, H., Medford, A., Norden, B., Putur, A., Bitman, E., Thant, W., Liu, T., Weipert, C., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2771 · Cited by 61
Self-citationTrastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding
Chen, W., Gupta, A., Mai, N., Nag, S., Lau, J. S., Singh, S., Chodera, J. D., Liu, B., de Stanchina, E., Pareja, F., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0647 · Cited by 50
Dark force rising: Reawakening and targeting of fetal-like stem cells in colorectal cancer
Fey, S. K., Vaquero-Siguero, N., & Jackstadt, R. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114270 · Cited by 32
Metadata
- Authors
- Bardia, A., Jhaveri, K., Kalinsky, K., Pernas, S., Tsurutani, J., Xu, B., Hamilton, E., Im, S.-A., Nowecki, Z., Sohn, J., Laurentiis, M. D., Jañez, N. M., Adamo, B., Lee, K. S., Jung, K. H., Rubovszky, G., Tseng, L.-M., Lu, Y.-S., Yuan, Y., Maxwell, M. J., Haddad, V., Khan, S. S., Rugo, H. S., & Pistilli, B.
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2023-06-30
- Volume
- 20
- Issue
- 8
- Pages
- 423-436
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- OpenAlex
- W4382631498
- Cited by
- 72
- References
- 12
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer. https://app.cochat.ai/papers/10.2217/fon-2023-0188
- The paper
- Bardia, A., Jhaveri, K., Kalinsky, K., Pernas, S., Tsurutani, J., Xu, B., Hamilton, E., Im, S.-A., Nowecki, Z., Sohn, J., Laurentiis, M. D., Jañez, N. M., Adamo, B., Lee, K. S., Jung, K. H., Rubovszky, G., Tseng, L.-M., Lu, Y.-S., Yuan, Y., . . . Pistilli, B. (2024). TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer. Future Oncology. https://doi.org/10.2217/fon-2023-0188
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.